Telomere dynamics in mice and humans

Seminars in Hematology

Volumn 50, Issue 2, 2013, Pages 165-174

  Calado, Rodrigo T ^a   Dumitriu, Bogdan ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; BONE MARROW DEPRESSION; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOMAL INSTABILITY; DKC1 GENE; DNA DAMAGE; DNA POLYMORPHISM; DYSKERATOSIS CONGENITA; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GLIOMA; HAPLOTYPE; HEMIZYGOSITY; HETEROZYGOSITY; HUMAN; KIDNEY CARCINOMA; LIFESPAN; LIVER CELL CARCINOMA; LUNG CANCER; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; TERC GENE; TERT GENE;

AGING; ANIMALS; HUMANS; MICE; MUTATION; NEOPLASMS; PHENOTYPE; TELOMERASE; TELOMERE;

EID: 84884695279     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.030     Document Type: Article

References (90)

1. Blackburn E.H. Switching and signaling at the telomere. Cell 2001, 106:661-673.
2. Olovnikov A.M. [Principle of marginotomy in template synthesis of polynucleotides]. Dokl Akad Nauk SSSR 1971, 201:1496-1499.
3. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
4. Collado M., Blasco M.A., Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130:223-233.
5. Shay J.W., Wright W.E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005, 26:867-874.
6. de Lange T. Protection of mammalian telomeres. Oncogene 2002, 21:532-540.
7. Sfeir A., de Lange T. Removal of shelterin reveals the telomere end-protection problem. Science 2012, 336:593-597.
8. Cohen S.B., Graham M.E., Lovrecz G.O., Bache N., Robinson P.J., Reddel R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315:1850-1853.
9. Calado R.T., Young N.S. Telomere diseases. N Engl J Med 2009, 361:2353-2365.
10. Aubert G., Lansdorp P.M. Telomeres and aging. Physiol Rev 2008, 88:557-579.
11. Jiang H., Schiffer E., Song Z., et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A 2008, 105:11299-11304.
12. Mollica L., Fleury I., Belisle C., Provost S., Roy D.C., Busque L. No association between telomere length and blood cell counts in elderly individuals. J Gerontol A Biol Sci Med Sci 2009, 64:965-967.
13. Wong L.S., Huzen J., van der Harst P., et al. Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure. European journal of heart failure 2010, 12:348-353.
14. Lipski P.S., Bennett M.K., Kelly P.J., James O.F. Ageing and duodenal morphometry. Journal of clinical pathology 1992, 45:450-452.
15. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., Kerber R.A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003, 361:393-395.
16. Brouilette S.W., Moore J.S., McMahon A.D., et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007, 369:107-114.
17. Samani N.J., Boultby R., Butler R., Thompson J.R., Goodall A.H. Telomere shortening in atherosclerosis. Lancet 2001, 358:472-473.
18. Benetos A., Gardner J.P., Zureik M., et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 2004, 43:182-185.
19. Aviv A. Genetics of leukocyte telomere length and its role in atherosclerosis. Mutat Res 2012, 730:68-74.
20. Valdes A.M., Andrew T., Gardner J.P., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005, 366:662-664.
21. Mirabello L., Huang W.Y., Wong J.Y., et al. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009, 8:405-413.
22. Cherkas L.F., Hunkin J.L., Kato B.S., et al. The association between physical activity in leisure time and leukocyte telomere length. Arch Intern Med 2008, 168:154-158.
23. Poch E., Carbonell P., Franco S., Diez-Juan A., Blasco M.A., Andres V. Short telomeres protect from diet-induced atherosclerosis in apolipoprotein E-null mice. FASEB J 2004, 18:418-420.
24. Sahin E., Colla S., Liesa M., et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470:359-365.
25. Savage S.A., Bertuch A.A. The genetics and clinical manifestations of telomere biology disorders. Genet Med 2010, 12:753-764.
26. Calado R.T., Regal J.A., Kleiner D.E., et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One 2009, 4:e7926.
27. Armanios M., Alder J.K., Parry E.M., Karim B., Strong M.A., Greider C.W. Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet 2009, 85:823-832.
28. Bischoff C., Petersen H.C., Graakjaer J., et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology 2006, 17:190-194.
29. Wright W.E., Shay J.W. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat Med 2000, 6:849-851.
30. Gomes N.M., Ryder O.A., Houck M.L., et al. Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging Cell 2011, 10:761-768.
31. Gorbunova V., Seluanov A. Coevolution of telomerase activity and body mass in mammals: from mice to beavers. Mech Ageing Dev 2009, 130:3-9.
32. von Zglinicki T., Saretzki G., Ladhoff J., d'Adda di Fagagna F., Jackson S.P. Human cell senescence as a DNA damage response. Mech Ageing Dev 2005, 126:111-117.
33. Winkler T, Hong SG, Decker JE, et al. Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia IPScs. J Clin Invest. In press,. http://dx.doi.org/10.1172/JC167146.
34. Farzaneh-Far R., Lin J., Epel E.S., Harris W.S., Blackburn E.H., Whooley M.A. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA 2010, 303:250-257.
35. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000, 110:768-779.
36. Armanios M.Y., Chen J.J., Cogan J.D., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356:1317-1326.
37. Jonassaint N.L., Guo N., Califano J.A., Montgomery E.A., Armanios M. The gastrointestinal manifestations of telomere-mediated disease. Aging Cell 2012.
38. Alter B.P., Giri N., Savage S.A., Rosenberg P.S. Cancer in dyskeratosis congenita. Blood 2009, 113:6549-6557.
39. Alter B.P., Baerlocher G.M., Savage S.A., et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007, 110:1439-1447.
40. Heiss N.S., Knight S.W., Vulliamy T.J., et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998, 19:32-38.
41. Calado R.T. Telomeres and marrow failure. Hematology Am Soc Hematol Educ Program 2009, 338-343.
42. Yamaguchi H., Calado R.T., Ly H., et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005, 352:1413-1424.
43. Tsakiri K.D., Cronkhite J.T., Kuan P.J., et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007, 104:7552-7557.
44. Calado R.T., Brudno J., Mehta P., et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 2011, 53:1600-1607.
45. Hartmann D., Srivastava U., Thaler M., et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 2011, 53:1608-1617.
46. Vulliamy T., Marrone A., Szydlo R., Walne A., Mason P.J., Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004, 36:447-449.
47. Ruggero D., Grisendi S., Piazza F., et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003, 299:259-262.
48. Chiang Y.J., Hemann M.T., Hathcock K.S., et al. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol 2004, 24:7024-7031.
49. Blasco M.A., Lee H.W., Hande M.P., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
50. Yoon A., Peng G., Brandenburger Y., et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006, 312:902-906.
51. Ebert B., Lipton J.M. Diamond Blackfan anemia and ribosome biogenesis: introduction. Semin Hematol 2011, 48:73-74.
52. Ellis S.R., Gleizes P.E. Diamond Blackfan anemia: ribosomal proteins going rogue. Semin Hematol 2011, 48:89-96.
53. Savage S.A., Giri N., Baerlocher G.M., Orr N., Lansdorp P.M., Alter B.P. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008, 82:501-509.
54. Walne A., Bhagat T., Kirwan M., et al. Mutations in the telomere capping complex in bone marrow failure and related syndromes. Haematologica 2012, 98:334-338.
55. Ballew B.J., Yeager M., Jacobs K., et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in dyskeratosis congenita. Hum Genet 2013, 132:473-480.
56. Hockemeyer D., Palm W., Wang R.C., Couto S.S., de Lange T. Engineered telomere degradation models dyskeratosis congenita. Genes Dev 2008, 22:1773-1785.
57. Chiang Y.J., Calado R.T., Hathcock K.S., Lansdorp P.M., Young N.S., Hodes R.J. Telomere length is inherited with resetting of the telomere set-point. Proc Natl Acad Sci U S A 2010, 107:10148-10153.
58. Liu T., Chung M.J., Ullenbruch M., et al. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Invest 2007, 117:3800-3809.
59. Alder J.K., Guo N., Kembou F., et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011, 184:904-912.
60. Boveri T. Concerning the origin of malignant tumours. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press and The Company of Biologists;. 2008.
61. Hemann M.T., Hackett J., A I.J., Greider C.W. Telomere length, telomere-binding proteins, and DNA damage signaling. Cold Spring Harb Symp Quant Biol 2000, 65:275-279.
62. Scheinberg P., Cooper J.N., Sloand E.M., Wu C.O., Calado R.T., Young N.S. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010, 304:1358-1364.
63. Calado R.T., Cooper J.N., Padilla-Nash H.M., et al. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia 2012, 26:700-707.
64. Calado R.T., Regal J.A., Hills M., et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A 2009, 106:1187-1192.
65. Chakraborty S., Sun C.L., Francisco L., et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009, 27:791-798.
66. Hastie N.D., Dempster M., Dunlop M.G., Thompson A.M., Green D.K., Allshire R.C. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990, 346:866-868.
67. O'Sullivan J.N., Bronner M.P., Brentnall T.A., et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002, 32:280-284.
68. Risques RA, Vaughan TL, Li X, et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007, 16:649-655.
69. Rafnar T., Sulem P., Stacey S.N., et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009, 41:221-227.
70. McKay J.D., Hung R.J., Gaborieau V., et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008, 40:1404-1406.
71. Hosgood H.D., Cawthon R., He X., Chanock S., Lan Q. Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility. Lung Cancer 2009, 66:157-161.
72. Shete S., Hosking F.J., Robertson L.B., et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009, 41:899-904.
73. Chen M., Ye Y., Yang H., et al. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 2009, 125:2342-2348.
74. Savage S.A., Chanock S.J., Lissowska J., et al. Genetic variation in five genes important in telomere biology and risk for breast cancer. Br J Cancer 2007, 97:832-836.
75. Zhang C., Tian Y.P., Wang Y., Guo F.H., Qin J.F., Ni H. hTERT rs2736098 genetic variants and susceptibility of hepatocellular carcinoma in the Chinese population: a case-control study. Hepatobil Pancreatic Dis Int 2013, 12:74-79.
76. Horn S., Figl A., Rachakonda P.S., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
77. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
78. Chin L., Artandi S.E., Shen Q., et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97:527-538.
79. Artandi S.E., Chang S., Lee S.L., et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000, 406:641-645.
80. Blanco R., Munoz P., Flores J.M., Klatt P., Blasco M.A. Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev 2007, 21:206-220.
81. Maser R.S., Choudhury B., Campbell P.J., et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007, 447:966-971.
82. Qi L., Strong M.A., Karim B.O., Armanios M., Huso D.L., Greider C.W. Short telomeres and ataxia-telangiectasia mutated deficiency cooperatively increase telomere dysfunction and suppress tumorigenesis. Cancer Res 2003, 63:8188-8196.
83. Siegl-Cachedenier I., Munoz P., Flores J.M., Klatt P., Blasco M.A. Deficient mismatch repair improves organismal fitness and survival of mice with dysfunctional telomeres. Genes Dev 2007, 21:2234-2247.
84. Khoo C.M., Carrasco D.R., Bosenberg M.W., Paik J.H., Depinho R.A. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc Natl Acad Sci U S A 2007, 104:3931-3936.
85. Feldser D.M., Greider C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007, 11:461-469.
86. Rudolph K.L., Millard M., Bosenberg M.W., DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001, 28:155-159.
87. Strong M.A., Vidal-Cardenas S.L., Karim B., Yu H., Guo N., Greider C.W. Phenotypes in mTERT(+)/(-) and mTERT(-)/(-) mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase. Mol Cell Biol 2011, 31:2369-2379.
88. Hao L.Y., Armanios M., Strong M.A., et al. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 2005, 123:1121-1131.
89. Seok J., Warren H.S., Cuenca A.G., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110:3507-3512.
90. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.